Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
Price to Sales: Discounted ValuationCompressed
Percentile Rank14
3Y CAGR-31.9%
5Y CAGR-12.1%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
-31.9%/yr
vs +10.2%/yr prior
5Y CAGR
-12.1%/yr
Recent deceleration
Acceleration
-42.2pp
Decelerating
Percentile
P14
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 3.91 | +20.6% |
| 2024 | 3.24 | +9.6% |
| 2023 | 2.96 | -76.2% |
| 2022 | 12.40 | +5.1% |
| 2021 | 11.80 | +58.4% |
| 2020 | 7.45 | +30.0% |
| 2019 | 5.73 | -31.8% |
| 2018 | 8.41 | -3.1% |
| 2017 | 8.68 | +52.1% |
| 2016 | 5.71 | - |